ReviewAmerican journal of cancer research2016

CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas.

Alexandra S Onea et al.PubMed ↗Full text ↗

No numbers read from the abstract.